In this episode of The Oncology Insights Podcast, Dr. Thomas Marron, Director of the Early Phase Trials Unit at Mount Sinai, explains how immunotherapy has reshaped cancer treatment. He discusses checkpoint inhibitors, cancer vaccines, cellular therapies, and the challenges of early-onset cancers. Learn how inflammation and aging impact immune response and what innovations are on the horizon. Listen now on all major platforms!

"Tumors often contain more immune cells than cancer cells, highlighting how critical immune dysfunction is in cancer development."

Meet the guest: Dr. Thomas Marron is Director of the Early Phase Trials Unit at Mount Sinai and a Professor of Medicine, Hematology, and Immunotherapy. With both an MD and PhD in Immunology, his research focuses on novel cancer immunotherapies and personalized vaccine strategies. He leads clinical trials that explore immune mechanisms and tumor biology in solid tumors.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (00:43) Introduction
• (01:57) Checkpoint inhibitor evolution
• (12:41) Cancer vaccine development
• (16:25) CAR-T therapy limits
• (20:01) Role of inflammation
• (25:38) Early-onset cancer trends
• (29:43) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast